Get the Stockscreener App
37.16
1.85%
-0.70
After Hours:
37.95
0.79
+2.13%
Dianthus Therapeutics Inc stock is traded at $37.16, with a volume of 996.91K.
It is down -1.85% in the last 24 hours and up +86.73% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$37.86
Open:
$38.47
24h Volume:
996.91K
Relative Volume:
1.90
Market Cap:
$1.20B
Revenue:
$4.85M
Net Income/Loss:
$-114.75M
P/E Ratio:
-11.43
EPS:
-3.25
Net Cash Flow:
$-100.36M
1W Performance:
+40.23%
1M Performance:
+86.73%
6M Performance:
+69.68%
1Y Performance:
+33.62%
1-Day Range:
$36.00
$38.59
1-Week Range:
$25.00
$38.59
52-Week Range:
$13.37
$38.59
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
37.16 | 1.22B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics Reports Positive Phase 2 Trial Results - MSN
Real time scanner hits for Dianthus Therapeutics Inc. explainedQuarterly Earnings Summary & Daily Oversold Bounce Ideas - Newser
Does Dianthus Therapeutics Inc. show high probability of rebound2025 Top Gainers & Fast Moving Stock Trade Plans - Newser
Price action breakdown for Dianthus Therapeutics Inc.Weekly Stock Summary & AI Powered Market Entry Ideas - Newser
Combining machine learning predictions for Dianthus Therapeutics Inc.July 2025 Retail & AI Enhanced Trade Execution Alerts - Newser
How to recover losses in Dianthus Therapeutics Inc. stockJuly 2025 Analyst Calls & Intraday High Probability Setup Alerts - Newser
Technical signs of recovery in Dianthus Therapeutics Inc.Quarterly Profit Review & Expert Approved Momentum Ideas - Newser
How hedge fund analytics apply to Dianthus Therapeutics Inc. stockJuly 2025 Rallies & Stock Timing and Entry Methods - Newser
Dianthus Therapeutics Target of Unusually High Options Trading (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase on Analyst Upgrade - MarketBeat
Is it too late to sell Dianthus Therapeutics Inc.July 2025 Pullbacks & Stepwise Trade Signal Implementation - Newser
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
visual analytics tools that track dianthus therapeutics inc. performance2025 Performance Recap & Weekly High Momentum Picks - Newser
Stifel Adjusts Price Target on Dianthus Therapeutics to $65 From $52, Maintains Buy Rating - MarketScreener
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - MSN
Wedbush Raises Price Target on Dianthus Therapeutics to $44 From $42, Keeps Outperform Rating - MarketScreener
analyzing recovery setups for dianthus therapeutics inc. investorsInsider Buying & Technical Entry and Exit Tips - Newser
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores - Benzinga
Using data filters to optimize entry into Dianthus Therapeutics Inc.Chart Signals & Long-Term Investment Growth Plans - Newser
Is Dianthus Therapeutics Inc. meeting your algorithmic filter criteriaMarket Risk Analysis & AI Driven Price Predictions - Newser
Visual analytics tools that track Dianthus Therapeutics Inc. performance2025 Major Catalysts & Community Verified Swing Trade Signals - Newser
Dianthus Therapeutics Closes Upsized $288 Million Offering - MarketScreener
Dianthus Therapeutics closes $288 million public offering - Investing.com
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Dianthus Therapeutics Closes $288 Million Public Offering to Advance Clinical Development of Antibody Therapeutics - Quiver Quantitative
$288 Million Biotech Raise: Dianthus Therapeutics Completes Major Public Offering for Autoimmune Programs - Stock Titan
Dianthus Therapeutics Raises $270M Through Stock Offering - TipRanks
Dianthus Therapeutics prices upsized $251M securities offering - MSN
Dianthus Therapeutics, Inc. $DNTH Holdings Increased by Octagon Capital Advisors LP - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Earns "Outperform" Rating from Raymond James Financial - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $67.00 at Robert W. Baird - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Cubist Systematic Strategies LLC Sells 32,948 Shares of Dianthus Therapeutics, Inc. $DNTH - Defense World
What data driven models say about Dianthus Therapeutics Inc.’s futureQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - Newser
Does Dianthus Therapeutics Inc. qualify in momentum factor screeningGap Up & Weekly Chart Analysis and Trade Guides - Newser
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownHere's What Happened - MarketBeat
Jefferies raises Dianthus Therapeutics stock price target to $66 on positive data - Investing.com Canada
Dianthus Therapeutics (NASDAQ:DNTH) Given Buy Rating at HC Wainwright - MarketBeat
Dianthus Therapeutics extends rally after boosted $251 mln equity raise - TradingView
Using fundamentals and technicals on Dianthus Therapeutics Inc.2025 Price Targets & Smart Swing Trading Techniques - Newser
Using RSI to spot recovery in Dianthus Therapeutics Inc.July 2025 Breakouts & Reliable Price Breakout Alerts - Newser
Dianthus Therapeutics Prices Upsized $251 Million Securities Offering - MarketScreener
Dianthus Therapeutics stock hits 52-week high at 34.74 USD By Investing.com - Investing.com Australia
Guggenheim Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
Analyzing recovery setups for Dianthus Therapeutics Inc. investors2025 Market Outlook & Risk Managed Investment Strategies - Newser
Dianthus Therapeutics’ (DNTH) “Outperform” Rating Reaffirmed at Raymond James Financial - Defense World
Dianthus Therapeutics prices upsized public offering at $251 million By Investing.com - Investing.com South Africa
Leading vs lagging indicators on Dianthus Therapeutics Inc. performanceMarket Performance Recap & AI Driven Stock Price Forecasts - Newser
Dianthus Therapeutics prices upsized public offering at $251 million - Investing.com
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering - The Manila Times
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):